Enabling Versatile Mono & Dual Payload ADCs Through Diverse Bundles, Including Azido & Drug Bundles - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Enabling Versatile Mono & Dual Payload ADCs Through Diverse Bundles, Including Azido & Drug Bundles

10:30 am - Monday 12th October 2026

Enabling flexible 2- or 4-site conjugation per antibody to allow precise control of payload ratios and combinations to develop mono or dual payload ADCs
Explaining how one integrated Drug Bundle conjugation process supports diverse ADC modalities through cysteine/thiol–maleimide conjugation and glycan-specific or MTGase-enabled click conjugation
Exploring how Drug Bundle-based ADCs have the potential to enhance stability and efficacy while helping overcome drug resistance

Speakers:

Hsing-Mao Chu

Hsing-Mao Chu

Chief Executive Officer

T-E Meds